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Background: Primary ciliary dyskinesia (PCD) is a rare disorder with variable disease progression. To date,
mutations in more than 20 different genes have been found. At present, PCD subtypes are described according
to the ultrastructural defect on transmission electron microscopy (TEM) of the motile cilia. PCD with normal
ultrastructure (NU) is rarely reported because it requires additional testing. Biallelic mutations in DNAH11 have
been described as one cause of PCD with NU.
The aim of our study was to describe the clinical characteristics of a large population of patients with PCD, in
relation to the ultrastructural defect. Additionally, we aimed to demonstrate the need for biopsy and cell culture
to reliably diagnose PCD, especially the NU subtype.
Methods: We retrospectively analyzed data from 206 patients with PCD. We compared the clinical characteristics,
lung function, microbiology and imaging results of 68 patients with PCD and NU to those of 90 patients with
dynein deficiencies and 41 patients with central pair abnormalities. In addition, we aimed to demonstrate the
robustness of the diagnosis of the NU subtype in cell culture by data from genetic analysis.
Results: PCD with NU comprised 33% (68/206) of all patients with PCD. Compared to other subtypes, patients
with PCD and NU had a similar frequency of upper and lower respiratory tract problems, as well as similar lung
function and imaging. With the currently widely applied approach, without cell culture, the diagnosis would
have been missed in 16% (11/68) of patients with NU. Genetic analysis was performed in 29/68 patients with
PCD and NU, and biallelic mutations were found in 79% (23/29) of tested patients.
Conclusions: We reported on the clinical characteristics of a large population of patients with PCD and NU.
We have shown that systematic performance of biopsy and cell culture increases sensitivity to detect PCD,
especially the subtype with NU.
PCD with NU has similar clinical characteristics as other PCD types and requires biopsy plus ciliogenesis in
culture for optimal diagnostic yield.
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Primary ciliary dyskinesia (PCD) is a rare disease [1],
caused by congenital abnormalities in both structure and
function of the motile cilia. It is characterized by upper
and lower respiratory tract infections, an increased in-
cidence of situs inversus (SI) and male infertility. It is
a genetically heterogeneous and predominantly autosomal
recessive disorder.
To date, mutations causing PCD have been described in
more than 20 genes. Specific genes are linked to distinct
ciliary ultrastructural abnormalities on transmission elec-
tron microscopy (TEM): mutations in DNAI1, DNAH5,
TXNDC3, DNAI2, DNAL1, CCDC114 and ARMC4
cause PCD with outer dynein arm (ODA) deficiency [2-4],
whereas mutations in DNAAF1, DNAAF2, DNAAF3,
HEATR2, LRRC6, CCDC103, DYX1C1, ZMYND10,
SPAG1 and C21orf59 cause combined inner dynein arm
(IDA) and ODA deficiency [2,5-8]. Absence or displace-
ment of the central microtubular pair (RSPH9, RSPH4A,
RSPH1, CCDC39, CCDC40) or absence of the nexin
links (CCDC164) have also been linked to specific genetic
defects [2,9]. DNAH11 and recently also HYDIN and
CCDC65 mutations are reported in some patients with
PCD and normal ultrastructure (NU) [10-12]. The repor-
ted prevalence of PCD with NU ranges from 10% to just
over 20% of all PCD cases [13,14]. However, it has pre-
viously been shown to be up to 28% in our lab [15].
Nevertheless, DNAH11 mutations are rare in population
studies [16] and the frequency of PCD with NU remains
under discussion.
The diagnosis of PCD is challenging and cannot rely
on signs and symptoms alone [17]. Absence of the ODA
and/or IDA or abnormalities of the central and periph-
eral microtubules can be detected by TEM. This tech-
nique was once proposed as the gold standard for
diagnosis, but will obviously miss PCD with NU. In PCD
with NU, only in vitro functional evaluation of the ciliary
motility can identify absent, diminished or uncoordin-
ated movement. However, secondary ciliary dyskinesia
(SCD), defined as a non-inherited dysfunction of the cilia
due to respiratory infection or exposure to cigarette
smoke, can complicate functional evaluation. SCD should
be excluded by repeated biopsy or by cell culture [18].
Because de novo regrowth of cilia is induced, SCD can be
excluded reliably, increasing specificity to diagnose PCD.
Nasal nitric oxide measurements are useful as a screening
test for PCD. They are low in most patients with PCD,
including those with normal ultrastructure. However, it is
not widely available and standardization is lacking.
The phenotypic features of children and adults with
PCD have been described previously [19,20], and attempts
have been made to detect a correlation between the
ultrastructural abnormality and clinical signs and symp-
toms [21-26]. However, only few data are available on thecharacteristics of PCD with NU and little is known about
the clinical characteristics of these patients in comparison
with those of patients with ‘classic’ PCD [11,12,16].
The main aim of our study was to describe clinical
characteristics of a large population of patients with
PCD, in relation to their ultrastructural defect. We also
aimed to demonstrate the need for biopsy and in vitro
ciliogenesis to confidently diagnose PCD, especially in
the NU subtype. Therefore, we retrospectively compared
the results from functional and structural evaluations of
the cilia before and after cell culture. Genetic analysis
was performed to support the diagnosis of PCD in the
subgroup of patients with NU.
Material and methods
We first described the clinical characteristics of patients
diagnosed with PCD, confirmed in the KU Leuven
Laboratory of Ciliary Function from January 1990 to
August 2012, with special focus on patients with the NU
subtype. Additionally, we described the laboratory findings
before and after cell culture. The study was approved
by the Ethical Committee of the University Hospital
of Leuven.
The KU Leuven Laboratory of Ciliary Function is the
only facility for in-depth evaluation of ciliary structure and
function by cell culture in Belgium. Patients were referred
from other centers. Biopsy samples were sent for diagnos-
tic evaluation of PCD. Screening tests such as nasal NO
measurements were performed in local patients, but not
in all patients referred from other centers because of lack
of equipment in some referring centers.
Assessment of clinical characteristics in patients with PCD
A standardized data sheet was used for data collection
including age at diagnosis (by nasal biopsy), gender,
ethnicity, parental consanguinity, presence of a sibling
with PCD and situs inversus including incomplete situs
abnormalities. Data were retrieved retrospectively from
the last available clinical records or by contacting pa-
tients or treating physicians.
The following signs and symptoms were evaluated as
lifetime prevalence (‘has ever had’): neonatal respiratory
problems (upper or lower respiratory tract symptoms
within the first 2 weeks of life), wheezing, lobectomy,
chronic sinusitis (nasal discharge during at least 8 weeks
or at least 4 episodes of acute rhinosinusitis each persist-
ing for ≥10 days, or abnormalities on sinus CT scan after
4 weeks of treatment), nasal polyps, sinus surgery, ear dis-
charge (purulent discharge via the ear canal), ear drum
perforation, hearing loss (conductive hearing loss ≥20 dB),
hearing aid, grommets insertion and adenotomy. Presence
or absence of pulmonary infiltrates, lobar consolidation/
atelectasis and bronchiectasis were scored on all avail-
able chest radiographs and/or CT scans. All respiratory
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available since diagnosis were evaluated for the presence
of H. influenzae, S. pneumoniae, S. aureus and/or P. aeru-
ginosa. Lifetime prevalence was reported as ‘has ever had
infection with’. Chronic colonization was defined as
persistence of the same pathogen in at least 3 sputum
samples over a period of at least 6 months. Nasal nitric
oxide (nNO) values were reported if known.
The ‘evaluation at last follow-up’ included age, weight,
height, BMI (body mass index) and lung function. Weight
and height were expressed as z-scores, according to the
Flemish growth curves [27]. BMI was calculated as weight
(kilograms)/height2 (meters) and also expressed as z-
scores, according to the Flemish growth curves. Spirom-
etry results were expressed as z-scores according to the
reference values of Quanjer and Stanojevic [28]. Symp-
toms scored at ‘current evaluation’ were: chronic cough
(coughing >3 days/week), chronic sputum production
(expectorating sputum >3 days/week), clubbing and
nasal secretions.
Diagnosis of PCD by cell culture, TEM and genetics
The flow chart for the diagnostic algorithm of PCD in
our center is shown in Figure 1. All patients included
underwent at least one nasal mucosal biopsy for func-
tional and structural evaluation of the respiratory cilia
before and after ciliogenesis in culture, even if the evalu-
ation before ciliogenesis was normal. In case insufficientNasal biopsy
CBF and coordination 
of ciliary beating
De novo ciliogenesis 
in culture
TEM
CBF and coordination 
of ciliary beating
TEM
Genetic analysis if 
TEM normal and 
functional evaluation 
abnormal
Figure 1 Flow chart of the diagnostic algorithm for PCD, used
in our center. Functional evaluation (CBF and coordination of ciliary
beating) was performed on the fresh biopsy, provided that cilia
were present. If sufficient material was obtained, a part of the biopsy
is prepared for TEM, the rest is brought in a cell culture system. After
ciliogenesis in culture, all the samples are evaluated for functional
and structural abnormalities. The diagnosis of PCD is made when
coordination after ciliogenesis in culture (marked in grey) is
abnormal. Genetic analysis is not performed routinely, but is
performed preferentially in patients with normal ultrastructure.material was available for both evaluations, all material
was brought into culture.
Nasal epithelial cells were enzymatically dissociated
from nasal biopsy specimens. If cilia were seen, ciliary
beat frequency (CBF) and coordination of ciliary activity
were evaluated. Ciliary movement was recorded with
digital high-speed video imaging using a MotionScope
high-speed camera mounted on an inverted Olympus
microscope. CBF was calculated with Matlab software
(version 6.5) (reference values obtained in our laboratory
were CBF 7.9 Hz, SD 1.8 at 23°C). Coordination of
ciliary motion was evaluated by directly observing move-
ment of fluid and debris in the medium and rotation or
migration of aggregates.
If sufficient material was present, TEM was performed
on the initial biopsy sample in order to identify any
structural abnormalities. Cross-sections were made in
the ciliary shaft, neither towards the base nor towards
the tip of the cilium. Per sample at least 50 transversal
cross-sections were evaluated. ODA deficiency was diag-
nosed when < 3 ODAs were visible, partial ODA defi-
ciency when <7 ODAs were observed. IDA deficiency was
defined as <1.5 IDA per cilium. Absence or displacement
of the central pair was indicative of PCD if present in >1/3
of the cilia. SCD score was calculated as a composite score
of membrane abnormalities (blebs, naked cilia, compound
cilia), disorganization of microtubules, abnormalities of
the central microtubular pair (absent, transposed, eccen-
tric, double) and peripheral microtubular abnormalities
(absent, supplementary, dislocated) [29]. SCD score >5%
was defined as abnormal.
Every biopsy sample was cultured irrespective of biopsy
results [30]. Cells were first grown in a monolayer to
expand the basal cell population without cilia (dediffe-
rentiation). Cells were then transferred to a suspension
medium to induce redifferentiation into ciliated epithelial
cells after 2–3 weeks (ciliogenesis). Ciliary activity (coord-
ination and CBF) and TEM were reevaluated after cell
culture. Abnormalities secondary to respiratory infection
and toxic substances thus disappeared and SCD and PCD
could be clearly distinguished [29]. Coordination of the
ciliary activity was subjectively evaluated. Normal coordin-
ation implied the observation of rotation of spheroids and
movement of debris in the medium due to the beating
motion of the cilia. PCD was defined as the absence of
coordinated ciliary activity after ciliogenesis in culture,
indicating that efficient ciliary transport was absent
(see Additional files 1, 2 and 3 for examples of normal
and abnormal coordination of ciliary activity). The validity
of this evaluation of coordination to distinguish PCD from
SCD was replicated by an independent group [31].
If patients consented and if DNA was available, genetic
analysis was performed in a subgroup of patients with NU.
Exome sequencing was performed to detect mutations in
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(DNA library preparation kit TruSeq DNA Sample Prep
kit v2, Illumina; Exome capturing kit SeqCap EZ Human
Exome Library v2.0, Nimblegen; Sequencing kits TruSeq
PE Cluster Kit v3-cBot-HS and TruSeq SBS Kit v3-HS,
Illumina; Sequencing apparatus Hiseq 2000, Illumina; Bio-
informatic analysis CLC Genomics Workbench, CLC Bio).
It should be noted that only a ‘partial’ exome was obtained
and that any mutation located in a gene not covered
by the partial exome, could therefore not be identified.
Sanger sequencing, performed by amplifying and sequen-
cing the coding exons and flanking intronic sequences of
DNAH11, was performed in most patients to confirm the
results of exome sequencing.Statistical analysis
Clinical characteristics were compared between PCD
with NU and PCD with dynein deficiencies (DD) (partial
or complete ODA deficiency or a combination of IDA
and ODA deficiency) and PCD with central pair abnor-
malities (CP).
A stratified analysis was performed per age group
(children below age 18 and adults from age 18 years on)
and according to presence of situs inversus and infection
with Pseudomonas.
Mann–Whitney U or Kruskal-Wallis test were used
for continuous variables when data were not normally
distributed. If there was a significant difference, paired
subgroup analysis was performed to identify which of
the groups was different. Proportions between groups
were compared using chi square statistics. Biometry and
lung function data were compared to the normal reference
values using one-sample t-test.
Functional analysis before and after cell culture was com-
pared using related samples Wilcoxon signed rank test.
A p-value <0.05 was defined as statistically significant.
SPSS 21.0 (IBM Corp., Armonk, NY) was used for statis-
tical analyses.Results
Between January 1990 and August 2012, PCD was diag-
nosed in 206 patients. Ninety patients were diagnosed
with PCD with DD (44%)(45 ODA deficiency, 37 partial
ODA deficiency and 8 IDA and ODA deficiency). PCD
with NU was diagnosed in 68 patients (33%), and PCD
with CP in 41 patients (20%) (22 with eccentric central
pair and IDA deficiency, 19 with absence of central pair).
PCD due to ciliary aplasia (n = 6) and peripheral micro-
tubular abnormalities (n = 1) was rare. Therefore, these
patients were excluded for further analysis. Of the re-
maining 199 patients, no clinical data could be obtained in
31. Data from 168 remaining patients were included
for analysis.Clinical characteristics in patients with PCD and
comparison between NU and other PCD types
Lifetime prevalence of symptoms
Clinical characteristics of the total PCD group and of
the 3 subpopulations are reported in Table 1. Lifetime
prevalence of most symptoms did not differ between the
subgroups. SI was significantly less frequent in the NU
and CP group compared to the DD group (p <0.05).
North African ancestry was more common in the CP
subgroup, and this was linked to higher incidence of
consanguinity (p <0.05).
Median age at diagnosis in the NU group was
10.2 years (IQR 4.4-21.8, range 0.0-61.9), two third of
the patients being diagnosed during childhood. Median
age at diagnosis in pediatric patients was 5.1 years (IQR
2.0-9.6, range 0.0-14.9). There was no significant differ-
ence in age at diagnosis between patients with NU, with
or without SI (p 0.71) (10.0 years, IQR 3.0-20.2, range
0.0-61.9 and 12.7 years, IQR 5.1-23.5, range 0.0-58.2,
respectively).
A history of neonatal respiratory problems was repor-
ted in 28 (47.5%) patients with NU. It was higher in
children with NU (n = 20/32, 63%) than in adults with
NU (n = 8/27, 29.6%) (p 0.012). Bronchiectasis was more
frequent in adults with NU (n = 24/27, 89%) than in chil-
dren with NU (n = 16/32, 50%) (p 0.001). Nasal polyps
were more prevalent in adults (n = 14/27, 51.9%) com-
pared to children (n = 5/32, 115.6%) (p 0.003) with NU.
Nevertheless, 8/29 (27.6%) children had already under-
gone sinus surgery for nasal polyps or recurrent sinusitis.
Nasal nitric oxide levels were available for 88/168 pa-
tients (41 with DD, 34 with NU and 13 with CC). There
was no difference between the subgroups. Normal values
at 300 ppb cut-off were observed in 7/34 patients with
NU, 6/41 with DD and 4/13 with CC (p 0.231).
Clinical characteristics at last follow-up
Clinical characteristics at last follow-up are shown in
Table 2. These did not differ between patients with NU
and those with DD or CP.
Current median age of the total group was 17.7 years
and this was similar in all subgroups. Weight and BMI
of the total group did not differ from that of the Flemish
reference population. Height was significantly lower
compared to that of healthy Flemish subjects (mean z-
score −0.53, 95% CI −0.85;-0.22, p 0.001). This was also
the case in the subgroups. Even when patients with
North African origin were excluded from analysis, the
mean z-score and 95% CI for height were still lower than
zero (i.e. -0.49, 95% CI −0.84; -0.15, p 0.006).
Mean FEV1 and FVC in patients with NU were lower than
normal (mean FEV1 z-score −1.45, 95% CI −1.90; -1.01;
mean FVC z-score −0.82, 95% CI −1.22; -0.42), even
when only children (n = 21) were evaluated (mean FEV1
Table 1 Lifetime prevalence of patient characteristics during follow-up
Total
population
(n = 168)
Normal
ultrastructure
(n = 59)
Dynein
deficiency
(n = 74)
Central pair
abnormalities
(n = 35)
p-value for
comparison
between groups
General Age at diagnosis in years (median - IQR) 9.9 (3.7–23.4) 10.2 (4.4–21.8) 10.8 (3.7–29.6) 8.7 (2.2–19.3) 0.60
Male gender, n (%) 91 (54.8) 32 (54.2) 39 (53.4) 20 (58.8) 0.85
North African ancestry, n (%) 38 (23.3) 8 (14.0) 12 (16.7) 18 (52.9)* 0.0001
Consanguinity, n (%) 33 (19.6) 9 (15.3) 12 (16.2) 12 (34.3)* 0.004
Sibling with PCD, n (%) 37 (22.0) 9 (15.3)* 17 (23.0) 11 (31.4)* 0.047
Situs inversus, n (%) 69 (41.1) 18 (30.5) 42 (56.8)* 9 (25.7) 0.001
Structural cardiac abnormality, n(%) 11 (6.5) 4 (8.7) 5 (9.6) 2 (9.1) 0.75
Lower respiratory tract Neonatal respiratory problems, n (%) 75 (44.6) 27 (45.8) 30 (40.5) 18 (51.4) 0.60
Wheezing, n (%) 79 (47.0) 28 (46.5) 37 (50.0) 14 (40.0) 0.33
Bronchiectasis, n (%) 114 (67.9) 40 (67.8) 51 (68.9) 23 (65.7) 0.51
Lobar collapse, n (%) 68 (40.5) 23 (39.0) 30 (40.5) 15 (42.9) 0.16
Pulmonary infiltrate, n (%) 100 (59.5) 37 (62.7) 43 (58.1) 20 (57.1) 0.29
Lobectomy, n (%) 15 (8.9) 4 (6.8) 7(9.5) 4 (11.4) 0.49
H. influenzae, n (%) 72 (42.9) 28 (47.5) 33 (44.6) 11 (31.4) 0.15
Strep. pneumoniae, n (%) 45 (26.8) 18 (30.5) 20 (27.0) 7 (20.0) 0.08
Staph. aureus, n (%) 28 (16.7) 9 (15.3) 17 (23.0) 2 (5.7) 0.07
Pseud. aeruginosa, n (%) 27 (16.1) 9 (15.3) 14 (18.9) 4 (11.4) 0.59
Upper respiratory tract Recurrent sinusitis, n (%) 111 (66.1) 41 (69.5) 52 (70.3) 18 (51.4) 0.67
Nasal polyps, n (%) 54 (32.1) 19 (32.2) 25 (33.8) 10 (28.6) 0.80
Sinus surgery, n (%) 68 (40.5) 27 (45.8) 31 (41.9) 10 (28.6) 0.79
nNO (ppb) (median – IQR) 52 (30–170) 64 (37–199) 40 (25–98) 89 (24–327) 0.15
Ear discharge, n (%) 70 (41.7) 30 (50.8) 26 (35.1) 14 (40.0) 0.33
Ear drum perforation, n (%) 35 (20.8) 15 (25.4) 11 (14.9) 9 (25.7) 0.15
Hearing loss, n (%) 58 (34.5) 20 (33.9) 30 (40.5) 8 (22.9) 0.33
Hearing aid, n (%) 10 (6.0) 2 (3.4) 5 (6.8) 3 (8.6) 0.38
Grommets insertion, n (%) 82 (48.8) 30 (50.8) 33 (44.6) 19 (54.3) 0.56
Adenotomy, n (%) 65 (38.7) 28 (47.5) 26 (35.1) 11 (31.4) 0.76
Legend: Table 1 shows general patient characteristics, incidence of specific lower and upper respiratory tract signs and symptoms in the total PCD group and in
the 3 subgroups. P-values for the comparison between the three subgroups (Kruskal-Wallis for continuous variables and χ2 for proportions) are shown in the last
column. If they revealed a significant result, pairwise comparisons were performed and the significant outlier was identified and marked with *.
IQR, inter quartile range.
nNO, nasal nitric oxide.
PCD, primary ciliary dyskinesia.
Data marked in bold denote significant differences.
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95% CI −1.28). The same was true in the other subgroups.
In 17/45 (38%) of the patients with NU, FEV1 z-score was
below −2, in 21/45 (47%) between −2 and 0 and in 15%
between 0 and 2. In this cross-sectional evaluation, FEV1
z-score did not worsen with age (−0.02 z-score per year
for NU, 95% CI −0.049; 0.017, p 0.325), but was already
abnormal at the age of 5. For a graphical illustration of the
lung function data, see Additional file 5.
In the total group of PCD patients, the Pseudomonas
positive patients were significantly older (n = 28, median
age 23.6 y) (p 0.017) and had significantly lower FEV1
z-scores (median FEV1 z-score −2.2) (p 0.032) than thePseudomonas negative patients (n = 140, median age
19.1 years, median FEV1 z-score −1.5). Chronic P. aerugi-
nosa infection was seen in 3 patients with NU, 3 patients
with DD and 2 patients with CP, all but one adults.
Ciliogenesis in culture and the diagnosis of PCD
Two hundred and six patients were diagnosed with PCD
and thus had abnormal ciliary coordination after cell
culture. This amounted to 6.5% of the 3190 evaluated
samples. In 75% of biopsies performed, the technique of
ciliogenesis in culture was successful at first biopsy.
Results for functional and structural evaluation before
and after ciliogenesis in culture for the total group and
Table 2 Patient characteristics at last follow-up
Total
(n = 168)
Normal
ultrastructure
(n = 59)
Dynein
deficiency
(n = 74)
Central pair
abnormalities
(n = 35)
p-value for
comparison
between groups
Age in years (median - IQR) 17.7 (9.5–28.1) 15.8 (9.7–26.7) 19.6 (10.9–31.9) 14.2 (6.7 – 24.5) 0.14
Years since diagnosis (median – IQR) 4.3 (0.0–11.4) 4.3 (0.4–9.0) 3.6 (0.0–12.8) 5.3 (0.0–11.5) 0.88
Weight z-score (mean - SD) −0.12 (1.25) −0.25 (1.25) 0.07 (1.33) −0.51 (0.97)* 0.16
Height z-score (mean - SD) −0.63 (1.23)* −0.53 (1.14)* −0.64 (1.26)* −0.91 (1.32)* 0.67
BMI z-score (mean - SD) 0.15 (1.23) 0.02 (1.17) 0.41 (1.22) −0.25 (1.31) 0.10
Chronic cough, n (%) 136 (81.0) 48 (81.4) 65 (87.8) 23 (65.7) 0.13
Chronic sputum production, n (%) 113 (81.9) 43 (81.1) 52 (83.9) 18 (78.3) 0.83
Clubbing, n (%) 31 (18.5) 10 (16.9) 16 (21.6) 5 (14.3) 0.57
Nasal secretions, n (%) 136 (81) 49 (83.1) 60 (81.1) 27 (77.1) 0.63
FEV1 z-score (median - IQR) (n = 112) −1.79 (−2.96; –0.76)* −1.47 (−2.67; –0.47)* −1.94 (−3.13; –1.19)* −2.34 (−3.61; –0.55)* 0.17
FVC z-score (median - IQR) (n = 112) −0.76 (−1.61; –0.15)* −0.54 (−1.43; 0.06)* −0.98 (−1.77; –0.21)* −0.77 (−2.05; –0.30)* 0.75
Legend: Table 2 shows clinical status at last follow-up in the total patient group and in the 3 subgroups. P-values for the comparison between the three subgroups
(Kruskal-Wallis for continuous variables and χ2 for proportions) are shown in the last column. * marks results that are significantly different from the reference
population. For FEV1 and FVC the total number of patients was only 112 because some patients were too young (<6 years) to perform spirometry (n = 25) or
because spirometry results were not available.
BMI, body mass index.
FEV1, forced expiratory volume in one second.
FVC, forced vital capacity.
IQR, inter quartile range.
SD, standard deviation.
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(40.7%) patients, no cilia were found for functional
evaluation on biopsy, either because of insufficient material
available or because cilia were not detected due to
extreme SCD.
In the NU subgroup, functional ciliary analysis was pos-
sible before as well as after ciliogenesis in 38 of 68 (56%)
patients. In 11/38 evaluation of both ciliary coordination
and CBF were assessed as normal in the biopsy (16% of
patients with final diagnosis of NU). However, they were
abnormal after cell culture. If only data prior to cell cul-
ture had been used, diagnosis of PCD with NU would
have been missed in at least 11 patients, representing 5%
of total PCD diagnoses. Repeat biopsy was performed in 6
of these 11 patients (3 patients had 2 biopsies, 2 patients
had 3 biopsies and 1 patient had 5 biopsies). All repeat
biopsies confirmed absence of ciliary coordination after
ciliogenesis and thereby confirmed the diagnosis of PCD
with NU. nNO was normal in only 1 of these patients, low
in 5 and missing in another 5 of these 11 patients.
The same discrepancy between functional evaluation be-
fore and after cell culture was observed in PCD with CP,
but rarely in PCD with DD (see Table 3). SCD disappears
after culture in the NU and DD group, but not in the CP
group. This is because the absence or displacement of the
central microtubular pair is in itself a marker of SCD. IDA
counts in the NU group did not significantly differ from a
non-PCD population (p 0.374).
In the NU group, CBF after culture was significantly
lower than in the biopsy (p 0.001), indicating that‘hyperfrequent’ beating disappears after ciliogenesis. This
discrepancy was not observed in the CP (p 0.674) and DD
group (p 0.170).
Genetic analysis of DNAH11 was performed in 29 of
68 patients with PCD and NU, including 6/11 patients
with discordant findings pre versus post ciliogenesis. In
total, PCD with NU could be confirmed genetically in
23/29 patients (79%) or in 19/25 families (76%). Biallelic
DNAH11 mutations were found in 21 patients, biallelic
HYDIN mutations in one patient and a homozygous
CCDC103 mutation in one other patient. The latter
mutation was previously described as a hypomorphic
mutation causing no abnormalities on TEM, but func-
tional abnormalities concordant with a diagnosis of PCD
[6]. In two patients, only one DNAH11 mutation could
be found. No mutations could be found in only 4/29
(14%) patients. See Additional file 6 for detailed informa-
tion on the results of exome sequencing.
Discussion
We described the clinical characteristics of our total popu-
lation of patients with PCD, and focused on the subgroup
of patients with PCD and NU. In addition, we described
the diagnostic pathway needed in order not to miss PCD
with NU. Of the 206 Belgian patients with PCD, patients
with NU emerged as an important subgroup.
In patients with PCD and NU, clinical characteristics
were similar compared to those of patients with PCD
and DD or CP. Our analysis confirmed that PCD
with NU have severe clinical symptoms: low height for
Table 3 Results of functional and ultrastructural evalution before and after cell culture
Normal values Normal
ultrastructure
(n = 68)
Dynein
deficiency
(n = 90)
Central pair
abnormalities
(n = 41)
p-value for
comparison
between 3 groups
Before After Before After Before After Before After
SAMPLE QUALITIY No cilia found
- For functional evaluation 30 (44%) 0 36 (40%) 0 15 (37%) 0 0.782 NA
- for TEM 22 (32%) 0 27 (30%) 0 13 (32%) 0 0.948 NA
Number of cilia counted for TEM 82 (45–114) 85 (59–132) 0.236 92 (58–160) 84 (49–129) 0.839 70 (52–126) 95 (61–125) 0.194 0.490 0.620
Total SCD (%) <5% 10 (5–22) 1 (0–4) 0.0001 13 (7–21) 1 (0–4) 0.0001 52 (31–70)* 52 (27–68)* 0.612 0.0001 0.0001
SPECIFIC
MEASUREMENTS
CBF (Hz) (median-IQR) 7.9 (1.8) (mean, SD) 5.8 (0–9.6) 0 (0–6.3) 0.001 0 (0–0)* 0 (0–0)* 0.674 5 (0–6.9) 4.4 (0–5.6) 0.170 0.0001 0.0001
N(%) of patients with normal CBF 18 (27%) 19 (28%) 4 (4%)* 11 (12%)* 14 (34%) 21 (51%) 0.0001 0.0001
N(%) of patients with Normal
coordination
17 (25%) 0 2 (2%)* 0 8 (20%) 0 0.0001 NA
N(%) of patients with normal CBF
and coordination
11 (16.2%) 0 1 (1.1%)* 0 6 (14.6%) 0 0.002 NA
N of ODA (median-IQR) 8.4 (0.8) (mean, SD) 8.3 (7.8–8.6) 8.4 (7.9–8.7) 0.238 2.3 (1.35–4.1)* 2.4 (1.4–4.6)* 0.233 8.6 (8.3–8.9) 8.6 (8.3–8.7) 0.221 0.0001 0.0001
N of IDA (median-IQR) 3.7 (1.4) (mean, SD) 3.2 (2.7–3.7)* 2.7 (2.3–3)* 0.001 2.9 (2.4–3.5) 2.1 (1.7–2.6) 0.0001 3.0 (1.3–3.6) 2.3 (1.1–2.7) 0.0001 0.036 0.0001
Legend: Sample specifications and results of functional (CBF and coordination of ciliary activity) and structural evaluation of the cilia before and after cell culture in the 3 subgroups. Normal values are reported in the
first column, based on our own laboratory references [18,32], and updated with more recent data. Each subsequent column represents a subgroup of PCD and each column is subdivided in a first column for
evaluation before cell culture (= in the biopsy) and a second column after cell culture. Individual results were compared before and after ciliogenesis (Wilcoxon signed rank test), and the result of these comparisons is
marked in italic. Comparison between the 3 PCD subgroups (Kruskal-Wallis or χ2 test) is presented in the last table. If the comparison revealed a significant result, pairwise comparisons were performed and the
significant outlier was identified and marked with *.
CBF, ciliary beat frequency.
IDA, inner dynein arm.
IQR, inter quartile range.
NA, not appropriate.
NU, normal ultrastructure.
ODA, outer dynein arm.
PCD, primary ciliary dyskinesia.
SCD, secondary ciliary dyskinesia.
SD, standard deviation.
TEM, transmission electron microscopy.
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lung function from an early age on and high prevalence of
bronchiectasis. The prevalence of bronchiectasis and nasal
polyps is higher in adults than in children, meaning that
the disease is progressive over time.
In our population of PCD with NU, the incidence of
SI was significantly lower than 50%, as was the case in
PCD with CP. The group of PCD with CP was a combi-
nation of patients with absence of the central pair
(RSPH4A or RSPH9 mutations) in whom SI did not
occur and patients with displacement of the central pair
(CCDC39 or CCDC40 mutations) in whom SI was
found. Similarly, the group of PCD with NU could be a
combination of patients with NU and patients with sub-
tle CP. Indeed, subtle abnormalities in the central pair
that cannot be visualized by TEM were recently reported
by Olbrich et al. [11], who described HYDIN mutations
as a cause of PCD with NU without SI. One patient in
our population with NU had 2 HYDIN mutations.
Recent data of the European Taskforce on PCD
demonstrated a median age at diagnosis of 5.3 years for
patients with a current age below 20 years [33]. When
only patients younger than 18 years were included, the
age at diagnosis in our center was similar (5.1 years).
However, one third of our population (59/168) was only
diagnosed in adulthood. This could be an indication that
the diagnosis can easily be missed or that patients with a
milder form only present towards adulthood.
Our cross-sectional data did not show any difference
in FEV1 or FVC between ages. Remarkably, however,
lung function was already found to be abnormal at the
age of 5 years. This observation suggests that destruction
of the lung parenchyma starts early, as previously sugges-
ted [34,35]. In addition, since complications like bron-
chiectasis are more frequent in older patients, disease
progression is most likely. Further prospective research in
a larger patient population is necessary to corroborate
these findings.
To demonstrate the need for cell culture to robustly
diagnose PCD with NU, we retrospectively analyzed our
diagnostic algorithm. We have clearly shown that PCD
with NU (and also with CP) can be missed if cell culture
is not an integral part of the diagnostic path. To date, a
combination of functional evaluation of the ciliary motil-
ity and TEM in a fresh biopsy sample has been the gold
standard to detect PCD with or without ultrastructural
abnormalities. Cell culture was to be reserved to diag-
nose PCD in selected, difficult cases [36,37]. We have
now shown that ciliogenesis in culture is essential not to
miss the subgroup of PCD with NU: in the current
population, 16% of the patients with PCD and NU would
have been missed (5% of the total PCD population). In a
subset of patients, the features of ciliary dysmotility only
became apparent after ciliogenesis in culture. Thus, cellculture increases both diagnostic specificity and sensitiv-
ity. Moreover, we have identified several new mutations
in DNAH11 in patients with NU. This confirms that the
culture technique is capable of correctly detecting PCD
with NU. Although no functional testing was performed,
most mutations were likely to be pathogenic, since most
of them were either stop codon or frameshift mutations.
We agree that it is difficult to understand that coordin-
ation is normal in a fresh biopsy sample and reverts to
abnormal after culture. We hypothesize that some growth
factors might be absent in the suspension medium, which
alters a hyperfrequent beating phenotype turn into a cilio-
static phenotype, leading to uncoordinated ciliary motion.
We are confident that cell death did not occur, because
cilia only reappeared on the last few days of suspension
culture. Misinterpretation is unlikely, as the result could
be confirmed repeatedly. Pifferi et al. have recently shown
the same phenomenon of normal evaluation of ciliary
coordination in the fresh biopsy and abnormal ciliary
coordination after culture in one patient with 2 DNAH11
mutations [31]. Also for patients with CP, we found a high
incidence of normal functional evaluation in the fresh
biopsy. Because central pair abnormalities are also a sign
of SCD, cell culture has an added value in PCD with CP.
Therefore, a repeat biopsy with a cell culture procedure
must be considered when clinical suspicion of PCD is high
and an alternative diagnosis is lacking.
One of the strengths of our study is population size. A
group of patients with PCD and NU has also been
described by Knowles et al. [16], but this study focused
on genetic diagnosis.
This study has some weaknesses. Although we did
measure CBF, we did not perform a computerized three-
dimensional ciliary beat pattern analysis, proposed as
gold standard by some centers [22]. It is impossible to
perform this technique on moving spheroids. Therefore,
we were not able to link the ultrastructural abnor-
malities to a specific beat pattern. However, ciliary beat
pattern analysis is difficult to interpret and abnormalities
may be very subtle [38]. Variability of beat pattern analysis
before versus after culture is another concern [38]. We
did not systematically include nNO measurement as a
diagnostic technique, because it was not available in most
of the referring centers. To date however, nNO mea-
surements have not been standardized and need further
validation.
We did not detect PCD with isolated IDA deficiency.
IDA deficiency is difficult to detect [39] and its existence
is debated [40]. Moreover, no gene mutations have been
described causing isolated IDA deficiency. It can be
hypothesized that some of the IDA deficiencies might be
misinterpreted as NU, but there was no significant
difference in IDA counts between PCD with NU and
control patients without PCD. The fact that we did not
Boon et al. Orphanet Journal of Rare Diseases 2014, 9:11 Page 9 of 10
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firm that it is part of SCD, as suggested previously [40].
One could question the usefulness of TEM in the diag-
nosis of PCD, as it does not add much information on
disease phenotype. TEM is expensive, time-consuming
and difficult to interpret. Additionally, it is insufficient as
stand-alone test since some abnormalities can be very
subtle. However, if genetic testing becomes routine in the
future, TEM morphology may guide genetic investigations.
Genetic analysis will aid diagnosis and will allow to exam-
ine genotype-phenotype correlations.
Conclusion
We have analyzed the clinical characteristics of a large
population with PCD. PCD with NU emerges as a large
subgroup and does not differ considerably from other
subgroups. We have shown the need for ciliogenesis in
culture so as not to miss PCD with NU. The robustness
of these diagnoses of PCD with NU is further proven by
the consistency of the findings in repeat biopsies as well
as by demonstration of mutations by genetic analysis.
Additional files
Additional file 1: Example of coordinated ciliary activity.
Coordinated ciliary movement can be observed: there is rotation of
spheroids in one direction.
Additional file 2: Example of coordinated ciliary activity.
Coordinated ciliary movement can be observed: there is active
movement along the ciliary border of a red blood cell.
Additional file 3: Example of uncoordinated ciliary activity.
Uncoordinated ciliary movement can be observed: there is no movement
of the spheroids, nor movement of debris or red blood cells in the
medium. Some cilia are static, others beat with a ‘hyperfrequent’ pattern.
Additional file 4: List of candidate genes that were used for exome
sequening analysis.
Additional file 5: Cross sectional data of FEV1 (a) and FVC (b) in the
subgroups according to age. Lung function results were available from
the age of 5 years. Results were available for 45 patients with NU,
51 patients with DD and 16 patients with CP. Different symbols refer
to different subtypes. Shaded areas denote −2 to +2 z-scores. The full
lines represent the regression line for the total group.
Additional file 6: Results of the exome sequencing analysis in 25
families with PCD and NU. Most of the mutations found, had not
previously been described in the literature (previously reported mutations
are underlined). Most of the mutations are likely to be pathogenic
because they are frameshift and/or stopcodon mutations (marked with *).
The other mutations were not previously reported as SNP (SNP137–
Common Variations database) and were thus also likely pathogenic. It
should be noted that we cannot prove the pathogenicity of some of
these mutations. In the family of DWS and DB, the asymptomatic father
was found to be heterozygous for the p.Arg2900* mutation, the
asymptomatic mother heterozygous for the c.10568 + 1G > A mutation,
and an asymptomatic sister was heterozygous for the c.10568 + 1G > A
mutation. This mutation involves the most important nucleotide of a
splice site and therefore is very likely a splice-site mutation. The sister of
VDE without PCD (confirmed on nasal biopsy) only carried the p.Arg1834-
Gly mutation. The p.Arg2068His and p.Trp3238Arg mutations have been
found in 3 patients with PCD. The p.Arg2068His and p.Trp3238Arg
mutations are therefore very likely two mutations in cis. Only one of
these two mutations might be pathogenic. The updated coding regionand mutation nomenclature was used [16]. ° only Sanger sequencing was
performed, no exome sequencing. Marked in grey: Patients with PCD
with normal ultrastructure and normal evaluation in biopsy. SS: situs soli-
tus. SI: situs inversus. ND: not done.
Abbreviations
CF: Cystic fibrosis; CP: Central pair abnormalities; DD: Dynein deficiency;
DNAH: Dynein axonemal heavy chain; ENT: Ear nose, throat; FEV1: Forced
expiratory volume in one second; FVC: Forced vital capacity; IDA: Inner
dynein arm; nNO: Nasal nitric oxide; NU: Normal ultrastructure; ODA: Outer
dynein arm; PCD: Primary ciliary dyskinesia; SCD: Secondary ciliary dyskinesia;
SI: Situs inversus; TEM: Transmission electron microscopy.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
MB, AS and KDB contributed to the design of the study, the collection and
analysis of the data and writing of the manuscript. HC and MJA contributed
to analysis of the genetic results, and reviewed the manuscript. MP, LJD, FLV,
SVD, AM, VG and MJO contributed to collection of the data and reviewed
the manuscript. All authors gave final approval for the manuscript.
Acknowledgements
We want to thank Valerie Vlaeminck for the preparation of the samples, and
performing the cell culture and TEM of the samples. We want to thank all
the primary care givers and the patients for supporting this research and
offering us information.
Partial results of this study have been presented at the European Respiratory
Society Annual Congress in Vienna, 1–5 September 2012. The contribution was
awarded the ERS grant for ‘Best abstract in Paediatric Respiratory Epidemiology’.
Funding
No funding was available for this research.
Author details
1Department of Pediatrics, Pediatric Pulmonology, University Hospital
Leuven, Leuven, Belgium. 2Center for Human Genetics, KUL, Leuven, Belgium.
3Department of Otorhinolaryngology, Head and Neck Surgery, University
Hospital Leuven, Leuven, Belgium. 4Department of Pulmonology, University
Hospital Leuven, Leuven, Belgium. 5Department of Pediatrics, Pediatric
Pulmonology, University Hospital Ghent, Ghent, Belgium. 6Department of
Pediatrics, Pediatric Pulmonology, Universitair Ziekenhuis Brussel UZB, Brussel,
Belgium. 7Department of Pediatrics, Pneumologie Pédiatrique et Mucoviscidose,
UCL St-Luc, Brussels, Belgium.
Received: 27 August 2013 Accepted: 15 January 2014
Published: 22 January 2014
References
1. Lucas JSA, Walker WT, Kuehni CE, Lazor R: Primary ciliary dyskinesia.
Eur Respir Monograph 2011, 54:201–217.
2. Zariwala MA, Omran H, Ferkol TW: The emerging genetics of primary
ciliary dyskinesia. Proc Am Thorac Soc 2011, 8:430–433.
3. Horvath J, Fliegauf M, Olbrich H, Kispert A, King SM, Mitchison H, Zariwala
MA, Knowles MR, Sudbrak R, Fekete G, et al: Identification and analysis of
axonemal dynein light chain 1 in primary ciliary dyskinesia patients.
Am J Respir Cell Mol Biol 2005, 33:41–47.
4. Onoufriadis A, Paff T, Antony D, Shoemark A, Micha D, Kuyt B, Schmidts M,
Petridi S, Dankert-Roelse JE, Haarman EG, et al: Splice-site mutations in the
axonemal outer dynein arm docking complex gene ccdc114 cause
primary ciliary dyskinesia. Am J Hum Genet 2013, 92:88–98.
5. Mitchison HM, Schmidts M, Loges NT, Freshour J, Dritsoula A, Hirst RA,
O’Callaghan C, Blau H, AL Dabbagh M, Olbrich H, et al: Mutations in
axonemal dynein assembly factor dnaaf3 cause primary ciliary
dyskinesia. Nat genet 2012, 44:381–389.
6. Panizzi JR, Becker-Heck A, Castleman VH, Al-Mutairi D, Liu Y, Loges NT,
Pathak N, Austin-Tse C, Sheridan E, Schmidts M, et al: ccdc103 mutations
cause primary ciliary dyskinesia by disrupting assembly of ciliary dynein
arms. Nat Genet 2012, 44:714–719.
Boon et al. Orphanet Journal of Rare Diseases 2014, 9:11 Page 10 of 10
http://www.ojrd.com/content/9/1/117. Horani A, Druley TE, Zariwala MA, Patel AC, Levinson BT, Van Arendonk LG,
Thornton KC, Giacalone JC, Albee AJ, Wilson KS, et al: Whole-exome
capture and sequencing identifies heatr2 mutation as a cause of primary
ciliary dyskinesia. Am J Hum Genet 2012, 91:685–693.
8. Kott E, Duquesnoy P, Copin B, Legendre M, Dastot-Le Moal F, Montantin G,
Jeanson L, Tamalet A, Papon JF, Siffroi JP, et al: Loss-of-function mutations
in lrrc6, a gene essential for proper axonemal assembly of inner and
outer dynein arms, cause primary ciliary dyskinesia. Am J Hum Genet
2012, 91:958–964.
9. Wirschell M, Olbrich H, Werner C, Tritschler D, Bower R, Sale WS, Loges NT,
Pennekamp P, Lindberg S, Stenram U, et al: The nexin-dynein regulatory
complex subunit drc1 is essential for motile cilia function in algae and
humans. Nat Genet 2013, 45:262–268.
10. Bartoloni L, Blouin JL, Pan Y, Gehrig C, Maiti AK, Scamuffa N, Rossier C,
Jorissen M, Armengot M, Meeks M, et al: Mutations in the dnah11
(axonemal heavy chain dynein type 11) gene cause one form of situs
inversus totalis and most likely primary ciliary dyskinesia. Proc Natl Acad
Sci USA 2002, 99:10282–10286.
11. Olbrich H, Schmidts M, Werner C, Onoufriadis A, Loges NT, Raidt J, Banki NF,
Shoemark A, Burgoyne T, Al Turki S, et al: Recessive hydin mutations cause
primary ciliary dyskinesia without randomization of left-right body
asymmetry. Am J Hum Genet 2012, 91:672–684.
12. Horani A, Brody SL, Ferkol TW, Shoseyov D, Wasserman MG, Ta-Shma A,
Wilson KS, Bayly PV, Amirav I, Cohen-Cymberknoh M, et al: ccdc65 mutation
causes primary ciliary dyskinesia with normal ultrastructure and
hyperkinetic cilia. Plos One 2013, 8:e72299.
13. Papon JF, Coste A, Roudot-Thoraval F, Boucherat M, Roger G, Tamalet A,
Vojtek AM, Amselem S, Escudier E: A 20-year experience of electron
microscopy in the diagnosis of primary ciliary dyskinesia. Eur Respir J
2010, 35:1057–1063.
14. Morillas HN Zariwala M, Knowles MR: Genetic causes of bronchiectasis:
primary ciliary dyskinesia. Respiration 2007, 74:252–263.
15. Jorissen M, Willems T, Van Der Schueren B, Verbeken E, De Boeck K:
Ultrastructural expression of primary ciliary dyskinesia after ciliogenesis
in culture. Acta Otorhinolaryngol Belg 2000, 54:343–356.
16. Knowles MR, Leigh MW, Carson JL, Davis SD, Dell SD, Ferkol TW, Olivier KN,
Sagel SD, Rosenfeld M, Burns KA, et al: Mutations of dnah11 in patients
with primary ciliary dyskinesia with normal ciliary ultrastructure.
Thorax 2011, 67:433–441.
17. Hogg C, Bush A: Genotyping in primary ciliary dyskinesia: ready for prime
time, or a fringe benefit? Thorax 2012, 67:377–378.
18. Jorissen M, Willems T, Van Der Schueren B: Ciliary function analysis for the
diagnosis of primary ciliary dyskinesia: advantages of ciliogenesis in
culture. Acta Otolaryngol 2000, 120:291–295.
19. Noone PG, Leigh MW, Sannuti A, Minnix SL, Carson JL, Hazucha M,
Zariwala MA, Knowles MR: Primary ciliary dyskinesia: diagnostic and
phenotypic features. Am J Respir Crit Care Med 2004, 169:459–467.
20. Kennedy MP, Omran H, Leigh MW, Dell S, Morgan L, Molina PL,
Robinson BV, Minnix SL, Olbrich H, Severin T, et al: Congenital heart
disease and other heterotaxic defects in a large cohort of patients
with primary ciliary dyskinesia. Circulation 2007, 115:2814–2821.
21. Vallet C, Escudier E, Roudot-Thoraval F, Blanchon S, Fauroux B, Beydon N,
Boule M, Vojtek A, Amselem S, Clement A, Tamalet A: Primary ciliary
dyskinesia presentation in 60 children according to ciliary ultrastructure.
Eur J Pediatr 2013, 172:1053–1060.
22. Chilvers M, Rutman A, O’callaghan C: Ciliary beat pattern is associated
with specific ultrastructural defects in primary ciliary dyskinesia.
J Allergy Clin Immunol 2003, 112:518–524.
23. Coren ME, Meeks M, Morrison I, Buchdahl RM, Bush A: Primary ciliary
dyskinesia: age at diagnosis and symptom history. Acta Paediatr 2002,
91:667–669.
24. Jain K, Padley SP, Goldstraw EJ, Kidd SJ, Hogg C, Biggart E, Bush A: Primary
ciliary dyskinesia in the paediatric population: range and severity of
radiological findings in a cohort of patients receiving tertiary care.
Clin Rradiol 2007, 62:986–993.
25. Min YG, Shin JS, Choi SH, Chi JG, Yoon CJ: Primary ciliary dyskinesia:
ultrastructural defects and clinical features. Rhinology 1995, 33:189–193.
26. Tamalet A, Clement A, Roudot-Thoraval F, Desmarquest P, Roger G, Boule
M, Millepied M, Baculard TA, Escudier E: Abnormal central complex is a
marker of severity in the presence of partial ciliary defect. Pediatrics 2001,
108:e86.27. Roelants M, Hauspie R, Hoppenbrouwers K: References for growth and
pubertal development from birth to 21 years in flanders, belgium.
Ann Hum Biol 2009, 36:680–694.
28. Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver B, Enright PL,
Hankinson JL, Lp MS, Zheng J, Stocks J: Multi-ethnic reference values for
spirometry for the 3–95 year age range: the global lung function 2012
equations. Eur Respir J 2012, 40:1324–1343.
29. Jorissen M, Willems T, Van Der Schueren B, Verbeken E: Secondary ciliary
dyskinesia is absent after ciliogenesis in culture. Acta Oto-Rhino-Laryngol
Belg 2000, 54:333–342.
30. Jorissen M, Van Der Schueren B, Tyberghein J, Van Der Berghe H, Cassiman
JJ: Ciliogenesis and coordinated ciliary beating in human nasal epithelial
cells cultured in vitro. Acta Oto-Rhino-Laryngol Belg 1989, 43:67–73.
31. Pifferi M, Bush A, Montemurro F, Pioggia G, Piras M, Tartarisco G, Di Cicco
M, Chinellato I, Cangiotti AM, Boner AL: Rapid diagnosis of primary ciliary
dyskinesia: cell culture and soft computing analysis. Eur Respir J 2013,
41:960–965.
32. Jorissen M, Willems T, Van Der Schueren B, Verbeken E: Dynein arms and
spokes after ciliogenesis in cultured respiratory epithelial cells from
non-pcd individuals. Acta Oto-Rhino-Laryngol Belg 2000, 54:325–332.
33. Kuehni CE, Frischer T, Strippoli MP, Maurer E, Bush A, Nielsen KG, Escribano
A, Lucas JS, Yiallouros P, Omran H, et al: Factors influencing age at
diagnosis of primary ciliary dyskinesia in european children. Eur Respir J
2010, 36:1248–1258.
34. Brown DE, Pittman JE, Leigh MW, Fordham L, Davis SD: Early lung disease
in young children with primary ciliary dyskinesia. Ped Pulmonol 2008,
43:514–516.
35. Marthin JK, Petersen N, Skovgaard LT, Nielsen KG: Lung function in patients
with primary ciliary dyskinesia: a cross-sectional and 3-decade
longitudinal study. AM J Respir Crit Care Med 2010, 181:1262–1268.
36. Bush A, Chodhari R, Collins N, Copeland F, Hall P, Harcourt J, Hariri M, Hogg
C, Lucas J, Mitchison HM, et al: Primary ciliary dyskinesia: current state of
the art. Arch Dis Child 2007, 92:1136–1140.
37. O’Callaghan C, Chilvers M, Hogg C, Bush A, Lucas J: Diagnosing primary
ciliary dyskinesia. Thorax 2007, 62:656–657.
38. Jackson CL, Goggin PM, Lucas JS: Ciliary beat pattern analysis below 37
degrees °C may increase risk of primary ciliary dyskinesia misdiagnosis.
Chest 2012, 142:543–544.
39. Escudier E, Couprie M, Duriez B, Roudot-Thoraval F, Millepied MC,
Pruliere-Escabasse V, Labatte L, Coste A: Computer-assisted analysis helps
detect inner dynein arm abnormalities. Am J Respir Crit Care Med 2002,
166:1257–1262.
40. O’Callaghan C, Rutman A, Williams GM, Hirst RA: Inner dynein arm
defects causing primary ciliary dyskinesia: repeat testing required.
Eur Respir J 2011, 38:603–607.
doi:10.1186/1750-1172-9-11
Cite this article as: Boon et al.: Primary ciliary dyskinesia: critical
evaluation of clinical symptoms and diagnosis in patients with normal
and abnormal ultrastructure. Orphanet Journal of Rare Diseases 2014 9:11.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
